Genomic landscape and expression profile of consensus molecular subtype four of colorectal cancer

Background Compared to other subtypes, the CMS4 subtype is associated with lacking of effective treatments and poorer survival rates. Methods A total of 24 patients with CRC were included in this study. DNA and RNA sequencing were performed to acquire somatic mutations and gene expression, respectively. MATH was used to quantify intratumoral heterogeneity. PPI and survival analyses were performed to identify hub DEGs. Reactome and KEGG analyses were performed to analyze the pathways of mutated or DEGs. Single-sample gene set enrichment analysis and Xcell were used to categorize the infiltration of immune cells. Results The CMS4 patients had a poorer PFS than CMS2/3. CTNNB1 and CCNE1 were common mutated genes in the CMS4 subtype, which were enriched in Wnt and cell cycle signaling pathways, respectively. The MATH score of CMS4 subtype was lower. SLC17A6 was a hub DEG. M2 macrophages were more infiltrated in the tumor microenvironment of CMS4 subtype. The CMS4 subtype tended to have an immunosuppressive microenvironment. Conclusion This study suggested new perspectives for exploring therapeutic strategies for the CMS4 subtype CRC.

[1]  V. Heinemann,et al.  Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212) , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. B. Borel Rinkes,et al.  Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study , 2022, Frontiers in Oncology.

[3]  Hui-Ying Zhao,et al.  Wnt signaling in colorectal cancer: pathogenic role and therapeutic target , 2022, Molecular cancer.

[4]  Lin Zhao,et al.  Clinical significance of FBXW7 loss of function in human cancers , 2022, Molecular Cancer.

[5]  J. Koster,et al.  Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity , 2022, British Journal of Cancer.

[6]  Jing Yang,et al.  B7 family member H4 induces epithelial-mesenchymal transition and promotes the proliferation, migration and invasion of colorectal cancer cells , 2021, Bioengineered.

[7]  U. Ghoshal,et al.  Survival analysis: A primer for the clinician scientists , 2021, Indian Journal of Gastroenterology.

[8]  V. Heinemann,et al.  Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). , 2021, European journal of cancer.

[9]  D. Lambrechts,et al.  Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer , 2021, Clinical Cancer Research.

[10]  D. Schrag,et al.  Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. , 2021, JAMA.

[11]  D. Hodge,et al.  Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. , 2021, JAMA network open.

[12]  Y. Xuan,et al.  B7-H4 induces epithelial-mesenchymal transition and promotes colorectal cancer stemness. , 2021, Pathology, research and practice.

[13]  H. Baba,et al.  Investigation of colorectal cancer in accordance with consensus molecular subtype classification , 2020, Annals of gastroenterological surgery.

[14]  K. Nakayama,et al.  Recent insight into the role of FBXW7 as a tumor suppressor. , 2020, Seminars in cancer biology.

[15]  H. Lenz,et al.  Molecular insight of regorafenib treatment for colorectal cancer. , 2019, Cancer treatment reviews.

[16]  D. Adams,et al.  Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis , 2019, Cancer cell.

[17]  S. Cai,et al.  A Risk Signature With Inflammatory and T Immune Cells Infiltration in Colorectal Cancer Predicting Distant Metastases and Efficiency of Chemotherapy , 2019, Front. Oncol..

[18]  A. Ruiz i Altaba,et al.  The protein secretion modulator TMED9 drives CNIH4/TGFα/GLI signaling opposing TMED3-WNT-TCF to promote colon cancer metastases , 2019, Oncogene.

[19]  Swee Jin Tan,et al.  Pan-cancer analysis connects tumor matrisome to immune response , 2019, npj Precision Oncology.

[20]  Shan Chen,et al.  Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin , 2019, Bioscience reports.

[21]  M. Bertagnolli,et al.  Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Okazaki,et al.  Anti‐tumor effects of mAb against l‐type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes , 2019, Cancer science.

[23]  J. Mariadason,et al.  The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  P. Kuppen,et al.  Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data , 2018, British Journal of Cancer.

[25]  Tsukasa Nakamura,et al.  Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation , 2018, International journal of molecular sciences.

[26]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[27]  R. Lothe,et al.  CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models , 2017, Scientific Reports.

[28]  Jeffrey S. Morris,et al.  The potential role of platelets in the consensus molecular subtypes of colorectal cancer , 2017, Cancer and Metastasis Reviews.

[29]  L. Ni,et al.  New B7 Family Checkpoints in Human Cancers , 2017, Molecular Cancer Therapeutics.

[30]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[31]  S. Miller,et al.  Potential targeting of B7‐H4 for the treatment of cancer , 2017, Immunological reviews.

[32]  S. Stain,et al.  Local and systemic Th17 immune response associated with advanced stage colon cancer. , 2017, The Journal of surgical research.

[33]  F. Markowetz,et al.  Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry , 2016, Clinical Cancer Research.

[34]  M. Katoh.  FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review) , 2016, International journal of molecular medicine.

[35]  Zhi-Qiang Ling,et al.  Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis , 2016, Medicine.

[36]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[37]  E. Mroz,et al.  Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas , 2015, PLoS medicine.

[38]  Chung-Yen Lin,et al.  cytoHubba: identifying hub objects and sub-networks from complex interactome , 2014, BMC Systems Biology.

[39]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[40]  Rui Zhang,et al.  B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. , 2014, Acta histochemica.

[41]  E. Adams.  Diverse antigen presentation by the Group 1 CD1 molecule, CD1c. , 2013, Molecular immunology.

[42]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[43]  J. Mao,et al.  Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. , 2013, Biochemical and biophysical research communications.

[44]  N. Pavlidis,et al.  Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes , 2013, BMC Cancer.

[45]  Zhi-ren Zhang,et al.  Macrophages in Tumor Microenvironments and the Progression of Tumors , 2012, Clinical & developmental immunology.

[46]  M. Ginsberg,et al.  CD98 at the crossroads of adaptive immunity and cancer , 2012, Journal of Cell Science.

[47]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[48]  R. Evans,et al.  STAT6 Transcription Factor Is a Facilitator of the Nuclear Receptor PPARγ-Regulated Gene Expression in Macrophages and Dendritic Cells , 2010, Immunity.

[49]  J. Neely,et al.  A practical guide to understanding Kaplan-Meier curves , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[50]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[51]  F. Greene.  Current TNM staging of colorectal cancer. , 2007, The Lancet. Oncology.

[52]  R. Tibshirani,et al.  Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. , 2007, Blood.

[53]  K. Jones,et al.  Wnt signaling: is the party in the nucleus? , 2006, Genes & development.

[54]  Fang Liu.  Smad3 phosphorylation by cyclin-dependent kinases. , 2006, Cytokine & growth factor reviews.

[55]  R. Labianca,et al.  Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  J. Ramos,et al.  Complementation of dominant suppression implicates CD98 in integrin activation , 1997, Nature.

[57]  R. Kurzrock,et al.  Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. , 2018, Cancer treatment reviews.

[58]  Louis Vermeulen,et al.  Classification of Colorectal Cancer in Molecular Subtypes by Immunohistochemistry. , 2018, Methods in molecular biology.

[59]  G. Fontanini,et al.  Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer , 2015, International journal of cancer.

[60]  Yonghong Xiao,et al.  SCFFBW 7 regulates cellular apoptosis by targeting MCL 1 for ubiquitylation and destruction , 2011 .

[61]  A. Sparks,et al.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. , 1998, Cancer research.